Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Sedatives Stories

2011-11-30 18:59:00

POINT RICHMOND, Calif., Nov. 30, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it will host a conference call to discuss the exercise by Purdue of its option to commercialize Intermezzo® (zolpidem tartrate) sublingual tablet C-IV in the United States. Conference Call InformationDate: Thursday, December 1, 2011Time: 8:30 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537 A simultaneous web cast of...

2011-11-30 18:10:00

POINT RICHMOND, Calif., Nov. 30, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that Purdue has exercised its option to commercialize Intermezzo® in the United States. Purdue plans to launch Intermezzo in the second quarter of 2012 and to invest approximately $100 million to support sales and marketing during the first year of commercialization. On November 23, 2011, the U.S. Food Drug Administration (FDA) approved...

89709824
2011-11-24 12:18:16

On Wednesday, the U.S. Food and Drug Administration (FDA) approved medication specifically designed for those who wake up in the middle of the night and can't fall back to sleep. Transcept Pharmaceuticals Intermezzo is a lower-dose formulation of Zolpidem, which was first approved in the U.S. in 1992 and is better known as Ambien. "This is the first time the FDA has approved a drug for this condition," theFDA said in a statement. "Intermezzo should only be used when a person has at...

2011-11-23 12:54:00

Point Richmond, Calif., Nov. 23, 2011 /PRNewswire/ --Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) has approved Intermezzo® (zolpidem tartrate sublingual tablet)( )C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo is not indicated for the treatment of middle-of-the-night insomnia when the patient has...

2011-11-23 12:33:00

POINT RICHMOND, Calif., Nov. 23, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the approval of Intermezzo® (zolpidem tartrate sublingual tablet) by the U.S. Food and Drug Administration. Conference Call...

2011-11-23 12:12:00

SILVER SPRING, Md., Nov. 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of...

2011-11-07 11:00:00

EL CAJON, Calif., Nov. 7, 2011 /PRNewswire/ -- As a neurologist who has discovered and described medical diseases, I (FAB) read the May 24, 2008, Charleston (WV) Gazette article "Vets taking Post Traumatic Stress Disorder drugs die in sleep," and opened and financed my own investigation into these unexplained deaths. Andrew White, Eric Layne, Nicholas Endicott and Derek Johnson, all in their twenties, were four West Virginia veterans who died in their sleep in early 2008. There were no...

2011-10-12 07:00:00

Healthy Answers offers many solutions to seasonally affected insomnia Delray Beach, FL (PRWEB) October 12, 2011 Insomnia sufferers find that it is harder to sleep during autumn and winter. Some people believe it is fewer hours of daylight that triggers the symptoms of seasonal affective disorder (SAD). Whatever the trigger, Healthy Answers offers many natural solutions to the insomnia dilemma. Sleep deprivation can cause many physical symptoms including lack of mental clarity, inability...

2011-09-27 16:17:00

POINT RICHMOND, Calif., Sept. 27, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo® (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration (FDA). The resubmission...

2011-09-14 15:05:00

POINT RICHMOND, Calif., Sept. 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today its plan to resubmit to the U.S. Food and Drug Administration (FDA) its New Drug Application (NDA) seeking approval of Intermezzo® (zolpidem tartrate sublingual tablet) for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. The plan to resubmit the Intermezzo®...